Skip to main content
Premium Trial:

Request an Annual Quote

Orchid’s Q3 Revenue Slides 4 Percent as Restructuring Helps Cut Loss 65 Percent

NEW YORK (GenomeWeb News) — Orchid Cellmark today said third-quarter revenues decreased 4 percent as R&D spending declined 16 percent and losses fell 65 percent.
 
Total receipts for the three months ended Sept. 30 decreased to $15.7 million from $16.4 million year over year.
 
R&D spending decreased to $316,000 from $376,000 year over year.
 
The company said losses declined to $1.3 million from $3.8 million in the year-ago period.
 
Orchid president and CEO Thomas Bologna said the quarterly improvement in the loss column reflects a “clear improvement” and “indicate[s] that our restructuring initiatives gained substantial traction in the third quarter.”
 
Orchid said it had around $12.5 million in cash and cash equivalents as of Sept. 30.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.